Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 337-343

  Beutner, Frank ^a   Brendel, Désiré ^a   Teupser, Daniel ^a,b   Sass, Kristina ^a   Baber, Ronny ^a   Mueller, Marc ^a,c   Ceglarek, Uta ^a   Thiery, Joachim ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c KLINIKUM LUDWIGSBURG   (Germany)

Author keywords

Atherosclerosis; Everolimus; Hypercholesterolemia; Mammalian target of rapamycin; MTOR; Proliferation signal inhibitor; PSI; Stage dependent efficiency of treatment

Indexed keywords

CD68 ANTIGEN; EVEROLIMUS; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA DISEASE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AORTA; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRACHIOCEPHALIC TRUNK; CHOLESTEROL; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PROTEIN KINASE INHIBITORS; RECEPTORS, LDL; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84861344785     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.003     Document Type: Article

References (26)

1. Elloso M.M., Azrolan N., Sehgal S.N., et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo e-deficient mice. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2003, 3:562-569.
2. Basso M.D., Nambi P., Adelman S.J. Effect of sirolimus on the cholesterol content of aortic arch in apoe knockout mice. Transplantation Proceedings 2003, 35:3136-3138.
3. Waksman R., Pakala R., Burnett M.S., et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoe knock-out mice. Cardiovascular Radiation Medicine 2003, 4:34-38.
4. Castro C., Campistol J.M., Sancho D., Sanchez-Madrid F., Casals E., Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 kip1-independent pathway. Atherosclerosis 2004, 172:31-38.
5. Mueller M.A., Beutner F., Teupser D., Ceglarek U., Thiery J. Prevention of atherosclerosis by the mtor inhibitor everolimus in ldlr-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008, 198:39-48.
6. Baetta R., Granata A., Canavesi M., et al. Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. The Journal of Pharmacology and Experimental Therapeutics 2009, 328:419-425.
7. Zhao L., Ding T., Cyrus T., et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the ldl receptor. British Journal of Pharmacology 2009, 156:774-785.
8. Gadioli A.L., Nogueira B.V., Arruda R.M., et al. Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein e-deficient mice. Brazilian Journal of Medical and Biological Research=Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica 2009, 42:1191-1195.
9. Jia L., Hui R.T. Everolimus, a promising medical therapy for coronary heart disease?. Medical Hypotheses 2009, 73:153-155.
10. Pakala R., Stabile E., Jang G.J., Clavijo L., Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein e knockout mice:inhibitory effect on monocyte chemotaxis. Journal of Cardiovascular Pharmacology 2005, 46:481-486.
11. Teupser D., Pavlides S., Tan M., Gutierrez-Ramos J.C., Kolbeck R., Breslow J.L. Major reduction of atherosclerosis in fractalkine (cx3cl1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proceedings of the National Academy of Sciences of the United States of America 2004, 17795-17800.
12. Kasiske B.L., de Mattos A., Flechner S.M., et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008, 8:1384-1392.
13. Hoogeveen R.C., Ballantyne C.M., Pownall H.J., et al. Effect of sirolimus on the metabolism of apob100-containing lipoproteins in renal transplant patients. Transplantation 2001, 72:1244-1250.
14. Ma K.L., Ruan X.Z., Powis S.H., Chen Y., Moorhead J.F., Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells:a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 2007, 84:1029-1036.
15. Morrisett J.D., Abdel-Fattah G., Hoogeveen R., et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research 2002, 43:1170-1180.
16. Tur M.D., Garrigue V., Vela C., et al. Apolipoprotein ciii is upregulated by anticalcineurins and rapamycin:implications in transplantation-induced dyslipidemia. Transplantation Proceedings 2000, 2783-2784.
17. Deters M., Kirchner G., Koal T., Resch K., Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Digestive Diseases and Sciences 2004, 49:30-37.
18. Glazer H.P., Osipov R.M., Clements R.T., Sellke F.W., Bianchi C. Hypercholesterolemia is associated with hyperactive cardiac mtorc1 and mtorc2 signaling. Cell Cycle 2009, 8:1738-1746.
19. Mathis A.S., Jin S., Friedman G.S., Peng F., Carl S.M., Knipp G.T. The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. Journal of Pharmaceutical Sciences 2007, 96:209-222.
20. Naoum J.J., Woodside K.J., Zhang S., Rychahou P.G., Hunter G.C. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in apo-e knockout mice. Transplantation Proceedings 2005, 1880-1884.
21. Park J., Ha H., Ahn H.J., et al. Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis in rat vascular smooth muscle cells. Transplantation Proceedings 2005, 3459-3462.
22. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. The Journal of Clinical Investigation 1996, 98:2277-2283.
23. Rajapakse A.G., Yepuri G., Carvas J.M., et al. Hyperactive s6k1 mediates oxidative stress and endothelial dysfunction in aging:inhibition by resveratrol. PloS One 2011, 6:e19237.
24. Verheye S., Martinet W., Kockx M.M., et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. Journal of the American College of Cardiology 2007, 49:706-715.
25. Yun M.R., Im D.S., Lee S.J., Woo J.W., Hong K.W., Bae S.S.K. im CD 4-hydroxynonenal contributes to macrophage foam cell formation through increased expression of class a scavenger receptor at the level of translation. Free Radical Biology and Medicine 2008, 45:177-183.
26. Ma K.L., Ruan X.Z., Powis S.H., Moorhead J.F., Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. American Journal of Physiology. Heart and Circulatory Physiology 2007, 292:H2721-H2728.